Fulvestrant
| Code | Size | Price |
|---|
| TAR-T2146-25mg | 25mg | £133.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T2146-100mg | 100mg | £230.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T2146-500mg | 500mg | £549.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Fulvestrant is a potent Estrogen Receptor antagonist (IC50: 9.4 nM).
CAS:
129453-61-8
Formula:
C32H47F5O3S
Molecular Weight:
606.77
Pathway:
Endocrinology/Hormones; Autophagy; Apoptosis
Purity:
0.9987
SMILES:
C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31
Target:
Apoptosis; Estrogen Receptor/ERR; Estrogen/progestogen Receptor; Autophagy
References
1. Wakeling AE, et al. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991 Aug 1;51(15):3867-73.
2. Huynh H, et al. Regulation of insulin-like growth factor I receptor expression by the pure antiestrogen ICI 182780. Clin Cancer Res. 1996 Dec;2(12):2037-42.
3. Zhao L, et al. Estrogenic agonist activity of ICI 182,780 (Faslodex) in hippocampal neurons: implications for basic science understanding of estrogen signaling and development of estrogen modulators with a dual therapeutic profile. J Pharmacol Exp Ther. 2006 Dec;319(3):1124-32.
4. Fernandes SA, et al. The anti-oestrogen fulvestrant (ICI 182,780) reduces the androgen receptor expression, ERK1/2 phosphorylation and cell proliferation in the rat ventral prostate. Int J Androl. 2011 Oct;34(5 Pt 1):486-500.
5. Chen D, Tan Y, Li Z, et al. Organoid cultures derived from patients with papillary thyroid cancer[J]. The Journal of Clinical Endocrinology & Metabolism. 2021, 106(5): 1410-1426.
6. Chen D, Tan Y, Li Z, et al. Organoid cultures derived from patients with papillary thyroid cancer[J]. The Journal of Clinical Endocrinology & Metabolism. 2021
7. Zhao Z, Xue F, Gu Y, et al. Crosstalk between the muscular estrogen receptor ? and BDNF/TrkB signaling alleviates metabolic syndrome via 7, 8-dihydroxyflavone in female mice[J]. Molecular Metabolism. 2020: 101149.